Kazia Therapeutics计划请求FDA进行类型C会议,讨论于胶质母细胞瘤(GBM)中的总体生存数据,以及与FDA倡议项目“先锋者”(Project Frontrunner)相一致的潜在NDA申请。
Kazia Therapeutics计划请求FDA进行类型C会议,讨论于胶质母细胞瘤(GBM)中的总体生存数据,以及与FDA倡议项目“先锋者”(Project Frontrunner)相一致的潜在NDA申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.